161 related articles for article (PubMed ID: 25207633)
1. The FTC v. Actavis roadmap: a guide to properly applying the rule of reason standard in reverse payment cases.
Sharkey N
J Leg Med; 2014; 35(3):445-66. PubMed ID: 25207633
[No Abstract] [Full Text] [Related]
2. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
Ritter M; Tempesta J; Ragusa P
Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307
[No Abstract] [Full Text] [Related]
3. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
4. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
Levy MS
Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
[TBL] [Abstract][Full Text] [Related]
5. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
6. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
7. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
Brockmeier MS
Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
[No Abstract] [Full Text] [Related]
8. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
9. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
Yvon AM
Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
[No Abstract] [Full Text] [Related]
10. Federal Trade Commission v. Actavis, Inc. and reverse-payment or pay-for-delay settlements.
Sherkow JS
Nat Biotechnol; 2013 Apr; 31(4):316-7. PubMed ID: 23563426
[No Abstract] [Full Text] [Related]
11. Will antitrust cops bust billion-dollar drug deals?
Barnett AA
J Am Health Care; 1994; 4(5):5-7. PubMed ID: 10142816
[No Abstract] [Full Text] [Related]
12. Generic drugs: the stalling game.
Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
[TBL] [Abstract][Full Text] [Related]
13. High-cost generic drugs--implications for patients and policymakers.
Alpern JD; Stauffer WM; Kesselheim AS
N Engl J Med; 2014 Nov; 371(20):1859-62. PubMed ID: 25390739
[TBL] [Abstract][Full Text] [Related]
14. Antitrust issues in the settlement of pharmaceutical patent disputes, Part II.
Leary TB
J Health Law; 2001; 34(4):657-71. PubMed ID: 11833411
[TBL] [Abstract][Full Text] [Related]
15. Brazil and USA at loggerheads over production of generic antiretrovirals.
Ahmad K
Lancet; 2001 Feb; 357(9254):453. PubMed ID: 11273079
[No Abstract] [Full Text] [Related]
16. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
Zain S
Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
[No Abstract] [Full Text] [Related]
17. Lowering the cost of prescription drugs.
Jindal B
J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276
[No Abstract] [Full Text] [Related]
18. RX for nosebleed prices.
Greenwald J
Time; 2001 May; 157(20):42-3. PubMed ID: 11383109
[No Abstract] [Full Text] [Related]
19. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
Sinha MS; Curfman GD; Carrier MA
JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
[No Abstract] [Full Text] [Related]
20. Delaying generic competition--corporate payoffs and the future of Plavix.
Shuchman M
N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
[No Abstract] [Full Text] [Related]
[Next] [New Search]
